Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
Hosted on MSN
Small molecule inhibitors restore normal BRAF structure, offering insight into cancer-causing mutations
The study, "BRAF oncogenic mutants evade autoinhibition through a common mechanism," published in Science, was conducted by co-first authors Hugo Lavoie, Ting Jin and Driss Lajoie, all of IRIC, in ...
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...
Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results